Dr Reddy’s CeleXA 10 mg: everyday SSRI for depression and anxiety

Dr Reddy’s CeleXA 10 mg tablets bring a generic version of the widely prescribed SSRI citalopram hydrobromide to the US market, targeting adults with major depressive disorder and certain anxiety-related conditions at a typically lower cost than branded options.

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 5:56 PM ET. Details in the imprint.

Dr Reddy’s CeleXA 10 mg tablets, a generic citalopram hydrobromide formulation, are positioned as an everyday prescription option for adults dealing with major depressive disorder and certain anxiety-related conditions in the US. As a generic equivalent to the brand-name SSRI Celexa, the product aims to combine established clinical use of citalopram with the typically more affordable pricing of generics, which is central to Dr. Reddy’s broader strategy in the US generics market. While exact retail prices vary by pharmacy and insurance plan, generics such as Dr Reddy’s CeleXA are often listed at markedly lower cash prices than brand-only alternatives, especially via major US chains and online pharmacy platforms.

What Dr Reddy’s CeleXA 10 mg is designed to do

Citalopram hydrobromide, the active ingredient in Dr Reddy’s CeleXA 10 mg, belongs to the class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is commonly prescribed for adults with major depressive disorder and, in many treatment settings, used off-label or as part of broader regimens for certain anxiety-related conditions, under the supervision of a licensed clinician. The medication is taken orally, usually once daily, and the 10 mg strength is often used either as a starting dose or as a maintenance dose in patients who require a lower daily amount, depending on individual response and tolerability.

As with the reference product, Dr Reddy’s generic formulation must demonstrate pharmaceutical equivalence and bioequivalence to the brand, which is a standard requirement for approval of generic drugs by the US Food and Drug Administration. That means the generic must contain the same active ingredient, strength, dosage form, and route of administration as the reference brand, and must show that it delivers citalopram into the bloodstream at a comparable rate and extent. For consumers and prescribers, this framework is designed to support substitution of the brand with a generic such as Dr Reddy’s CeleXA 10 mg where medically appropriate.

The 10 mg tablet strength plays a specific role in dosing flexibility. In clinical practice, physicians often start patients at a lower dose to gauge tolerability, particularly in individuals who are more sensitive to SSRIs or are taking other medications. Having an explicitly labeled 10 mg tablet makes it easier to implement gradual dose titration, simplifies adherence for patients who might otherwise split larger tablets, and supports long-term treatment at lower doses where that is sufficient. In addition to the 10 mg strength, generic citalopram products are widely available in higher strengths such as 20 mg and 40 mg, enabling stepwise dose adjustments.

From a patient perspective, the tablet format is designed for once-daily oral administration, with or without food, which aligns with typical SSRI prescribing patterns. Packaging for US generics is usually optimized for pharmacy dispensing, with bottles configured for 30-day or 90-day supply, depending on the prescription and insurance coverage. Pharmacists may substitute Dr Reddy’s CeleXA 10 mg for branded Celexa when allowed by state substitution laws and when the prescribing physician has not restricted substitution, a practice that supports cost savings across the healthcare system.

Positioning in the US pharmacy and generics landscape

Dr. Reddy’s Laboratories is one of the prominent Indian-headquartered manufacturers supplying generic medicines, active pharmaceutical ingredients, and complex formulations to the US market. The company’s US portfolio spans multiple therapeutic areas, including central nervous system, cardiovascular, oncology, and anti-infective medicines, with more than 190 marketed drugs and dozens of APIs. In this context, a generic SSRI such as CeleXA 10 mg is part of a broader push to maintain a presence in high-volume primary-care categories like depression and anxiety, where affordability and consistent supply are key differentiators.

Availability for US patients typically runs through major pharmacy chains, regional drugstores, and large online dispensing platforms. US consumers can obtain Dr Reddy’s citalopram products with a valid prescription, and many pharmacy benefit managers and health plans favor generics on their formularies to control overall drug spend. That positioning supports volume-driven economics: even with lower per-tablet pricing, high prescription volumes make antidepressants a relevant revenue contributor for generics makers focused on mature therapeutic classes.

Pricing of generic antidepressants in the US is influenced by factors like the number of competitors, purchasing concentration among large pharmacy chains, and ongoing negotiations with pharmacy benefit managers. While public price lists fluctuate, generic citalopram products have generally moved into a low-to-mid price segment versus the now largely off-patent branded reference, particularly in the cash-pay market. Discount drug-card programs and insurance copay structures often further compress out-of-pocket costs for patients, and products from companies like Dr. Reddy’s benefit from being among the widely distributed options in this environment.

Quality and regulatory compliance are central issues for US buyers, especially when sourcing from global manufacturers. Dr. Reddy’s, like other established Indian manufacturers, operates US FDA-inspected facilities and participates in global quality initiatives as part of its export strategy. For prescribers and pharmacists, the fact that a generic has met FDA bioequivalence and manufacturing standards is a key precondition for selection; for consumers, the main observable differences versus brands are often the tablet’s color, shape, imprint, and the name printed on pharmacy labels, rather than the underlying clinical effect.

In terms of competition, Dr Reddy’s CeleXA 10 mg competes with other manufacturers’ citalopram hydrobromide generics as well as with alternative SSRIs such as sertraline, fluoxetine, and escitalopram, which are themselves available from multiple generic companies. The choice of molecule is primarily a clinical decision based on patient history, side-effect profile, and prior response, but the availability of multiple bioequivalent citalopram products tends to keep prices under pressure. Within that crowded space, Dr. Reddy’s leverages its scale in API and finished-dosage manufacturing and its distribution relationships in the US generics market to keep its products on pharmacy shelves.

For people managing chronic mood or anxiety disorders, long-term daily adherence can make multi-year cost and supply reliability especially important. Generic options like Dr Reddy’s CeleXA 10 mg are part of the toolbox that clinicians and patients use to match clinical needs with a manageable cost structure. Anyone considering citalopram therapy should work closely with a qualified healthcare professional, as the drug has well-documented benefits but also known risks and side effects, including potential interactions with other medications, withdrawal symptoms if abruptly discontinued, and the need for careful monitoring, particularly when therapy is initiated or doses are changed.

From a company perspective, antidepressants sit alongside cardiovascular, gastrointestinal, and oncology drugs in Dr. Reddy’s global generics portfolio, rather than defining the business on their own. The firm’s overall strategy includes expanding beyond traditional generics into more complex generics, injectables, and value-added formulations, as well as biosimilars, to diversify earnings and reduce dependence on any single therapeutic class. For consumers watching the product space, this means that a tablet like CeleXA 10 mg is one strand in a much larger pipeline of established and new launches that Dr. Reddy’s uses to compete with other multinational generics companies.

Dr. Reddy’s positions the US as a priority export market, and management routinely highlights North America revenues in its investor communications, underscoring how US approvals and launches contribute to group performance. Against that backdrop, products such as generic citalopram tablets help maintain shelf presence in primary-care categories, complementing more specialized offerings in oncology and complex generics. Shares of Dr. Reddy’s Laboratories (INE089A01023, ticker RDY) traded at $13.36 on the New York Stock Exchange as of June 12, 2026.

Dr Reddy’s CeleXA 10 mg at a glance

• Product: Dr Reddy’s CeleXA 10 mg tablets (citalopram hydrobromide)
• Manufacturer: Dr Reddy
• Category: Lifestyle/consumer prescription medication (SSRI antidepressant)
• Launch date: Generic citalopram hydrobromide widely available in US market in the 2010s as patents on the reference brand expired
• MSRP / Price: Generic pricing varies by pharmacy and insurance; typically positioned below brand-name Celexa in US cash-pay and copay tiers
• Availability: With prescription via US retail pharmacies, mail-order services, and major pharmacy chains; subject to state substitution rules
• Target audience: Adults diagnosed with major depressive disorder or certain anxiety-related conditions, under medical supervision
• Key feature / USP: FDA-approved generic equivalent to branded Celexa, designed to offer established SSRI therapy with the cost advantages of a generic product

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.